Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 1, 2009, Pages 155-160

  Leonard, Steven N ^a,b   Rybak, Michael J ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glycopeptide resistance; hGISA; hVISA; MRSA

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE SIMULATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MODEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL VIABILITY; MODELS, THEORETICAL; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 57649201334     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn439     Document Type: Article

References (29)

1. Jevons MP. 'Celbenin'-resistant staphylococci. Br Med J 1961; 1: 124-5.
2. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
3. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
4. Centers for Disease Control and Prevetion (CDC). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565-7.
5. Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
6. Howden BP, Johnson PD, Ward PB et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 3039-47.
7. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
8. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-5.
9. Garnier F, Chainier D, Walsh T et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006; 57: 146-9.
10. Rybak MJ, Leonard SN, Rossi KL et al. Characterization of vancomycin heteroresistant Staphylococcus aureus (hVISA) from the Detroit Metropolitan area over a 22-year period 1986-2007. J Clin Microbiol 2008; 46: 2950-4.
11. Nunes AP, Schuenck RP, Bastos CC et al. Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia. Braz J Infect Dis 2007; 11: 345-50.
12. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998; 42: 100-7.
13. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant Gram-positive organisms. Antimicrob Agents Chemother 2003; 47: 1598-603.
14. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
15. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
16. Mwangi MM, Wu SW, Zhou Y et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104: 9451-6.
17. Patel JB, Jevitt LA, Hageman J et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42 1652-3.
18. Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006; 50: 4195-7.
19. Clinical and Laboratory Standards Institute. Methods for Dilution Susceptibility Tests for Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
20. Wootton M, MacGowan AP, Walsh TR et al. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007; 45: 329-32.
21. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-9.
22. Benvenuto M, Benziger DP, Yankelev S et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-9.
23. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: E394-434.
24. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
25. Lodise TP, Lomaestro B, Graves J et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
26. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
27. Rose WE, Leonard SN, Sakoulas G et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 831-6.
28. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
29. Marco F, de la Maria CG, Armero Y et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2538-43.